34. Neurofibromatosis
120 clinical trials,   182 drugs   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways

Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02839720
(ClinicalTrials.gov)
April 11, 201720/7/2016Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous NeurofibromaPilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)Cutaneous Neurofibroma;Neurofibromatosis Type 1;Optic Nerve GliomaOther: Laboratory Biomarker Analysis;Drug: Selumetinib;Drug: Selumetinib SulfateNational Cancer Institute (NCI)NULLRecruiting18 YearsN/AAll24Phase 2United States
2NCT02415153
(ClinicalTrials.gov)
July 14, 201513/4/2015Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsA Phase I Trial of Pomalidomide for Children With Recurrent, Progressive, or Refractory CNS TumorsNeurofibromatosis Type 1;Recurrent Childhood Brain Stem Glioma;Recurrent Childhood Visual Pathway Glioma;Recurrent Primary Central Nervous System Neoplasm;Refractory Primary Central Nervous System NeoplasmOther: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: PomalidomideNational Cancer Institute (NCI)NULLActive, not recruiting3 Years20 YearsAll29Phase 1United States
3NCT01089101
(ClinicalTrials.gov)
April 19, 201017/3/2010Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade GliomaA Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade GliomaLow Grade Glioma;Recurrent Childhood Pilocytic Astrocytoma;Recurrent Neurofibromatosis Type 1;Recurrent Visual Pathway Glioma;Refractory Neurofibromatosis Type 1;Refractory Visual Pathway GliomaOther: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: SelumetinibNational Cancer Institute (NCI)NULLRecruiting3 Years21 YearsAll220Phase 1;Phase 2United States